Hypercoagulable states and Buerger's disease;Aspetti di trombofilia nel morbo di Buerger

Recenti Progressi in Medicina

Volumn 91, Issue 9, 2000, Pages 436-440

  Caramaschi, Paola ^a,b   Biasi, Domenico ^a   Volpe, Alessandro ^a   Carletto, Antonio ^a   Bambara, Lisa Maria ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b NONE   (Italy)

Author keywords

Buerger's disease; Hypercoagulable states; Hyperhomocysteinemia; Lipoprotein(a); Thromboangiitis obliterans

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ILOPROST; IMMUNOLOGICAL ADJUVANT; VASODILATOR AGENT;

ADULT; ANGIOGRAPHY; ARTICLE; BUERGER DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING CESSATION; THROMBOPHILIA;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANGIOGRAPHY; ASPIRIN; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; ILOPROST; MALE; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SMOKING CESSATION; THROMBOANGIITIS OBLITERANS; THROMBOPHILIA; VASODILATOR AGENTS;

EID: 0034266156     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Buerger L. Thromboangiitis obliterans: a study of the vascular lesions leading to presenile gangrene. Am J Med Sci 1908; 136: 567-80.
2. Matsushita M, Nishikimi N, Sakurai T, Nimura Y. Decrease in prevalence of Buerger's disease in Japan. Surgery 1998; 124: 498-502.
3. Mills JL, Taylor LM, Porter JM. Buerger's disease in the modern era. Am J Surg 1987; 154: 123-9.
4. Wessler S, Ming SC, Gurewich V, Freiman DG. Critical evaluation of thromboangiitis obliterans. The case against Buerger's disease. N Engl J Med 1960; 262: 1149-60.
5. McKusick VA, Harris WS, Ottesen OK, Goodman RM, Sheley WM, Bloodwell RD. Buerger's disease: a distinct clinical and pathologic entity. JAMA 1962; 181: 93-100.
6. Lie JT. Thromboangiitis obliterans (Buerger's disease) in women. Medicine (Baltimore) 1987; 66: 65-72.
7. Hada M, Sakihama T, Kamiya K, Tasaka K, Ueno A. Cellular and humoral immune responses to vascular components in thromboangiitis obliterans. Angiology 1993; 44: 533-40.
8. De Bakey ME, Cohen B. Buerger's disease: follow up study of World War II Army cases. Springfield: Charles C Thomas, 1963; p. 21.
9. O'Dell J, Linder J, Markin S, Moore GF. Thromboangiitis obliterans (Buerger's disease) and smokeless tobacco. Arthritis Rheum. 1987; 9: 1054-6.
10. Powell JT. Vascular damage from smoking: disease mechanism at the arterial wall. Vase Med 1998; 3: 21-8.
11. Hutchison S. Smoking as a risk factor for endothelial disfunction. Can J Cardiol 1998; 14: 20-2.
12. McLoughlin GA, Helsey GR, Evans CC, Chapman DM. Association of HLA-A9 and HLA-B5 with Buerger's disease. Br Med J 1976; 2: 1165-6.
13. Papa M, Bass A, Adar R, et al. Autoimmune mechanism in thromboangiitis obliterans (Buerger's disease). The role of tobacco antigen and the major histocompatiblity complex. Surgery 1992; 111: 527-31.
14. Pietraszek MH, Choudhury NA, Koyano K, Sakaguchi S, Kamiya T, Urano T. Enhanced platelet response to serotonin in Buerger's disease. Thromb Res 1990; 60: 241-6.
15. Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR. The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease). Circulation 1990; 82: 3-8.
16. Lie JT. Thromboangiitis obliterans (Buerger's disease) revisited. Pathol Annu 1988; 23: 257-91
17. Shionoya S, Ban I, Nakata Y, et al. Diagnosis, pathology, and treatment of Buerger's disease. Surgery 1974; 75: 695-700.
18. Kobayashi M, Ito M, Nakagawa A, Nishikimi N, Nimura Y. Immunohistochemical analysis of arterial wall cellular infiltration in Buerger's disease (endarteritis obliterans). J Vase Surg 1999; 29: 451-8.
19. Borner C, Heidrich H. Long-term follow-up of thromboangiitis obliterans. VASA 1998; 27: 80-6.
20. th ed 1997; 1738-9.
21. Fiessinger JN, Schafer M. Trial of Iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. Lancet 1990; 335: 555-7.
22. Athanassiou P, McHale J, Dikeou S, Laffan M. Buerger's disease and protein S deficiency: successful treatment with prostacyclin. Clin Exp Reumatol 1995; 13: 371-5.
23. Caramaschi P, Biasi D, Carletto A, Poli G, Bambara LM. A case of Buerger's disease with very high levels of lipoprotein(a). Clin Exp Rheumatol 1996; 14: 347-8.
24. Biasi D, Caramaschi P, Carletto A, Pasqualini R, Bambara LM. A case of Buerger's disease associated with high levels of lipoprotein(a). Clin Rheumatol 1999; 18: 59-60.
25. Takami S, Kubo M, Yamashita S, Kameda-Takemura K. High levels of serum lipoprotein(a) in patients with ischemic heart disease with normal coronary angiogram and thromboangiitis obliterans. Atherosclerosis 1995; 112: 253-60.
26. Takami S, Yamashita S, Kihara S. Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation 1998; 97: 721-8.
27. Edelberg JM, Gonzales-Gronow, Pizzo SV. Lipoprotein(a) inhibits streptokinase-mediated activation of human plasminogen. Biochemistry 1989; 28: 2370-4.
28. Olin JW, Childs MB, Bartholomew JR, Calabrese HL, Young JR. Anticardiolipin and homocysteine levels in patients with thromboangiitis obliterans. Arthritis Rheum 1996; 39: S47.
29. Mercié P, Baste JC, Sassoust G, Ged C. Factor V Leiden, mild hyperhomocyst(e)inemia and Buerger's disease. Microvascular Research 1998; 55: 271-2.
30. Caramaschi P, Biasi D, Carletto A, et al. Three cases of Buerger's disease associated with hyperhomocysteinemia. Clin Exp Rheum (in corso di stampa).
31. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111-28.
32. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90: 1-11.
33. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
34. Harker LS, Ross R, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis. J Clin Invest 1976; 58: 731-41.
35. Rodgers GM, Conn MT. Homocysteine, and atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990; 75: 895-901.
36. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987; 262: 10098-103.